IGF-I gene variability is associated with an increased risk for AD

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 556.e3-556.e11

  Vargas, Teo ^a,b   Martinez Garcia, Ana ^b,c   Antequera, Desiree ^a,b   Vilella, Elisabet ^d   Clarimon, Jordi ^b,e   Mateo, Ignacio ^b,f   Sanchez Juan, Pascual ^b,f   Rodriguez Rodriguez, Eloy ^b,f   Frank, Ana ^g   Rosich Estrago, Marcel ^d   Lleo, Alberto ^b,e   Molina Porcel, Laura ^e   Blesa, Rafael ^e   Gomez Isla, Teresa ^b,e   Combarros, Onofre ^b,f   Bermejo Pareja, Felix ^a,b   Valdivieso, Fernando ^b,c   Bullido, Maria Jesus ^b,c   Carro, Eva ^a,b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Alzheimer's disease; IGF I; Polymorphism; Risk factor; Serum levels

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; SOMATOMEDIN C;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952902179     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.10.017     Document Type: Article

References (60)

1. Aberg M.A., Aberg N.D., Hedbäcker H., Oscarsson J., Eriksson P.S. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J. Neurosci 2000, 20:2896-2903.
2. Alvarez A., Cacabelos R., Sanpedro C., García-Fantini M., Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging 2007, 28:533-536.
3. Al-Zahrani A., Sandhu M.S., Luben R.N., Thompson D., Baynes C., Pooley K.A., Luccarini C., Munday H., Perkins B., Smith P., Pharoah P.D., Wareham N.J., Easton D.F., Ponder B.A., Dunning A.M. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum. Mol. Genet 2006, 15:1-10.
4. Antequera D., Vargas T., Ugalde C., Spuch C., Molina J.A., Ferrer I., Bermejo-Pareja F., Carro E. Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease. Neurobiol. Dis 2009, 36:42-50.
5. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
6. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet 2007, 39:17-23.
7. Canzian F., McKay J.D., Cleveland R.J., Dossus L., Biessy C., Rinaldi S., Landi S., Boillot C., Monnier S., Chajès V., Clavel-Chapelon F., Téhard B., Chang-Claude J., Linseisen J., Lahmann P.H., Pischon T., Trichopoulos D., Trichopoulou A., Zilis D., Palli D., Tumino R., Vineis P., Berrino F., Bueno-de-Mesquita H.B., van Gils C.H., Peeters P.H., Pera G., Ardanaz E., Chirlaque M.D., Quirós J.R., Larrañaga N., Martínez-García C., Allen N.E., Key T.J., Bingham S.A., Khaw K.T., Slimani N., Norat T., Riboli E., Kaaks R. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-1 and IGFBP-3 and breast cancer risk: results from the EPIC study. Br. J. Cancer 2006, 94:299-307.
8. Carrasquillo M.M., Belbin O., Hunter T.A., Ma L., Bisceglio G.D., Zou F., Crook J.E., Pankratz V.S., Dickson D.W., Graff-Radford N.R., Petersen R.C., Morgan K., Younkin S.G. Replication of CLU, CR1, and PICALM associations with Alzheimer's disease. Arch. Neurol 2010, 67:961-964.
9. Carro E., Nuñez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci 2000, 20:2926-2933.
10. Carro E., Spuch C., Trejo J.L., Antequera D., Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor. I. J. Neurosci 2005, 25:10884-10893.
11. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol 2004, 490:127-133.
12. Carro E., Trejo J.L., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci 2001, 21:5678-5684.
13. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med 2002, 8:1390-1397.
14. Carro E., Trejo J.L., Gerber A., Loetscher H., Torrado J., Metzger F., Torres-Aleman I. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging 2006, 27:1250-1257.
15. Carro E., Trejo J.L., Spuch C., Bohl D., Heard J.M., Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?. Neurobiol. Aging 2006, 27:1618-1631.
16. Chauhan V., Ji L., Chauhan A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 2008, 9:381-389.
17. Chodobski A., Szmydynger-Chodobska J. Choroid plexus: target for polypeptides and site of their synthesis. Microsc. Res. Tech 2001, 52:65-82.
18. Garcia J., Ahmadi A., Wonnacott A., Sutcliffe W., Nagga K., Soderkvist P., Marcusson J. Association of insulin-like growth factor-1 receptor polymorphism in dementia. Dement. Geriatr. Cogn. Disord 2006, 22:439-444.
19. Giedraitis V., Kilander L., Degerman-Gunnarsson M., Sundelöf J., Axelsson T., Syvänen A.C., Lannfelt L., Glaser A. Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement. Geriatr. Cogn. Disord. 2009, 27:59-68.
20. Guerreiro R.J., Gustafson D.R., Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2010.03.025.
21. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schürmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hüll M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van-Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Mühleisen T.W., Nöthen M.M., Moebus S., Jöckel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet 2009, 41:1088-1093.
22. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
23. Hirko A.C., Meyer E.M., King M.A., Hughes J.A. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol. Ther 2007, 15:1623-1629.
24. Hong M., Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem 1997, 272:19547-19553.
25. Hund E., Linke R.P., Willig R., Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 2001, 56:431-435.
26. Kiuru S. Gelsolin-related familial amyloidosis Finnish type (FAF), and its variant found worldwide. Amyloid 1998, 5:55-66.
27. Koya R.C., Fujita H., Shimizu S., Ohtsu M., Takimoto M., Tsujimoto Y., Kuzumaki N. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J. Biol. Chem 2000, 275:15343-15349.
28. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fiévet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossô P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanché H., Dartigues J.F., Tzourio C., Gut I., Van-Broeckhoven C., Alpérovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet 2009, 41. European Alzheimer's Disease Initiative Investigators, 1094-1049.
29. Lopez-Lopez C., LeRoith D., Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9833-9838.
30. Martínez-García A., Sastre I., Tenorio R., Bullido M.J. SNP genotyping with FRET probes. Optimizing the resolution of heterozygotes. Mol. Cell. Probes 2004, 18:211-214.
31. Matsumoto N., Kitayama H., Kitada M., Kimura K., Noda M., Ide C. Isolation of a set of genes expressed in the choroid plexus of the mouse using suppression subtractive hybridization. Neuroscience 2003, 117:405-415.
32. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci 2003, 23:29-33.
33. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
34. Murialdo G., Barreca A., Nobili F., Rollero A., Timossi G., Gianelli M.V., Copello F., Rodriguez G., Polleri A. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J. Endocrinol. Invest 2001, 24:139-146.
35. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cogn. Disord 1999, 10:446-451.
36. Niikura T., Hashimoto Y., Okamoto T., Abe Y., Yasukawa T., Kawasumi M., Hiraki T., Kita Y., Terashita K., Kouyama K., Nishimoto I. Insulinlike growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J. Neurosci 2001, 21:1902-1910.
37. Nuñez A., Carro E., Torres-Aleman I. Insulin-like growth factor I modifies electrophysiological properties of rat brain stem neurons. J. Neurophysiol 2003, 89:3008-3017.
38. Qiao H., Koya R.C., Nakagawa K., Tanaka H., Fujita H., Takimoto M., Kuzumaki N. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol. Aging 2005, 26:849-855.
39. Qin X., Hauser E.R., Schmidt S. Ordered subset analysis for case-control studies. Genet. Epidemiol 2010, 34:407-417.
40. Remes A.M., Finnilä S., Mononen H., Tuominen H., Takalo R., Herva R., Majamaa K. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 2004, 63:234-240.
41. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
42. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis 2005, 8:247-268.
43. Salehi Z., Mashayekhi F., Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors 2008, 33:99-106.
44. Saraiva M.J. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat 2001, 17:493-503.
45. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci 2003, 23:7084-7092.
46. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Küstermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., Brüning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3100-3105.
47. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci 2000, 924:17-25.
48. Sleegers K., Lambert J.C., Bertram L., Cruts M., Amouyel P., Van-Broeckhoven C. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010, 26:84-93.
49. Strazielle N., Ghersi-Egea J.F. Choroid plexus in the central nervous system: biology and physiopathology. J. Neuropathol. Exp. Neurol 2000, 59:561-574.
50. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
51. Tham A., Nordberg A., Grissom F.E., Carlsson-Skwirut C., Viitanen M., Sara V.R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect 1993, 5:165-176.
52. Trejo J.L., Carro E., Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J. Neurosci 2001, 21:1628-1634.
53. van Dam P.S., Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur. J. Pharmacol 2004, 490:87-95.
54. Vardy E.R., Rice P.J., Bowie P.C., Holmes J.D., Grant P.J., Hooper N.M. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J. Alzheimers Dis 2007, 12:285-290.
55. Vargas T., Bullido M.J., Martinez-Garcia A., Antequera D., Clarimon J., Rosich-Estrago M., Martin-Requero A., Mateo I., Rodriguez-Rodriguez E., Vilella-Cuadrada E., Frank A., Lleo A., Molina-Porcel L., Blesa R., Combarros O., Gomez-Isla T., Bermejo-Pareja F., Valdivieso F., Carro E. A megalin polymorphism associated with promoter activity and Alzheimer's disease risk. Am. J. Med. Genet. B Neuropsychiatr. Genet 2010, 153B:895-902.
56. Vidal R., Garzuly F., Budka H., Lalowski M., Linke R.P., Brittig F., Frangione B., Wisniewski T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am. J. Pathol 1996, 148:361-366.
57. Weller R.O., Yow H.Y., Preston S.D., Mazanti I., Nicoll J.A. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. Ann. N. Y. Acad. Sci 2002, 977:162-168.
58. Willis P.E., Chadan S., Baracos V., Parkhouse W.S. Acute exercise attenuates age-associated resistance to insulin-like growth factor. I. Am. J. Physiol 1997, 272:397-404.
59. Wilson H.S., Skodol A. Special report: DSM-IV: overview and examination of major changes. Arch. Psychiatr. Nurs 1994, 8:340-347.
60. Zhao W.Q., Lacor P.N., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J. Biol. Chem 2009, 284:18742-18753.